ATE229031T1 - 6,7-oxygenierte steroide und deren verwendung - Google Patents

6,7-oxygenierte steroide und deren verwendung

Info

Publication number
ATE229031T1
ATE229031T1 AT97929071T AT97929071T ATE229031T1 AT E229031 T1 ATE229031 T1 AT E229031T1 AT 97929071 T AT97929071 T AT 97929071T AT 97929071 T AT97929071 T AT 97929071T AT E229031 T1 ATE229031 T1 AT E229031T1
Authority
AT
Austria
Prior art keywords
oxygen substitution
steroids
disclosed
steroid
functionality
Prior art date
Application number
AT97929071T
Other languages
English (en)
Inventor
David L Burgoyne
Yaping Shen
John M Langlands
Christine Rogers
Joseph H-L Chau
Edward Piers
Hassan Salari
Original Assignee
Inflazyme Pharm Ltd
Univ British Columbia
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazyme Pharm Ltd, Univ British Columbia, Univ Alberta filed Critical Inflazyme Pharm Ltd
Application granted granted Critical
Publication of ATE229031T1 publication Critical patent/ATE229031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT97929071T 1996-07-11 1997-07-11 6,7-oxygenierte steroide und deren verwendung ATE229031T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2345096P 1996-07-11 1996-07-11
US67964296A 1996-07-12 1996-07-12
PCT/CA1997/000490 WO1998002450A2 (en) 1996-07-11 1997-07-11 6,7-oxygenated steroids and uses related thereto

Publications (1)

Publication Number Publication Date
ATE229031T1 true ATE229031T1 (de) 2002-12-15

Family

ID=26697171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929071T ATE229031T1 (de) 1996-07-11 1997-07-11 6,7-oxygenierte steroide und deren verwendung

Country Status (13)

Country Link
US (5) US6046185A (de)
EP (1) EP0917534B1 (de)
JP (1) JP2001503732A (de)
KR (1) KR100533436B1 (de)
AT (1) ATE229031T1 (de)
AU (1) AU722815B2 (de)
BR (1) BR9710353A (de)
CA (1) CA2259981C (de)
DE (1) DE69717633T2 (de)
ES (1) ES2187788T3 (de)
NZ (1) NZ333731A (de)
RU (1) RU2196143C2 (de)
WO (1) WO1998002450A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US6946445B1 (en) 1998-03-13 2005-09-20 The University Of British Columbia Therapeutic chemokine receptor antagonists
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
RU2291873C2 (ru) 2000-04-28 2007-01-20 Инфлазим Фармасьютикалз Лимитед 3-амино-6,7-дикислородсодержащие стероиды, фармацевтическая композиция, способы лечения
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US20030008853A1 (en) * 2001-05-21 2003-01-09 Alcon, Inc. Method for treating dry eye disorders
BR0209965A (pt) 2001-05-21 2004-04-06 Alcon Inc Uso de inibidores de nf-kappab para tratar distúrbios do olho seco
US6696580B2 (en) 2001-05-22 2004-02-24 Inflazyme Pharmaceuticals Ltd. Process for the production of 6,7-diols of steroidal compounds
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
GB0217930D0 (en) * 2002-08-02 2002-09-11 Glycologic Ltd A chemical carrier
WO2004089304A2 (en) * 2003-04-01 2004-10-21 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
CA2521883C (en) * 2003-04-15 2013-09-17 Inflazyme Pharmaceuticals Ltd. Indene derivatives as pharmaceutical agents
CA2582231A1 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
JP2008531584A (ja) * 2005-02-25 2008-08-14 エフィカス・インコーポレイテッド マタタビ属を含む組成物およびそれを用いる方法
CN101395159A (zh) * 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN103626818B (zh) * 2012-03-08 2016-03-30 广州市赛普特医药科技有限公司 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法
BR112015022577A2 (pt) 2013-03-14 2017-07-18 Aquinox Pharmaceuticals Canada Inc moduladores ship1 e métodos relacionados a esse
EP2970122B1 (de) 2013-03-14 2019-05-08 Aquinox Pharmaceuticals (Canada) Inc. Ship1-modulatoren
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
US9944590B2 (en) 2015-06-26 2018-04-17 Aquinox Pharmaceuticals (Canada) Inc. Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
WO2017127753A1 (en) 2016-01-20 2017-07-27 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
US20190047939A1 (en) 2016-03-02 2019-02-14 Patheon Austria Gmbh & Co Kg Process and intermediates for the production of 17(20)-ene b-seco steroids
JP6892278B2 (ja) * 2017-02-10 2021-06-23 あすか製薬株式会社 １５−オキソステロイド化合物及びその製造方法
CN112543753A (zh) 2018-04-06 2021-03-23 塔罗制药公司 可用于治疗疼痛和炎症的茚衍生物
AU2019247496A1 (en) 2018-04-06 2020-10-22 Taro Pharmaceuticals Inc. Indene derivatives useful in treating pain and inflammation
ES2960542T3 (es) * 2018-04-06 2024-03-05 Taro Pharmaceuticals Inc Derivados de hexadecahidro-1H-ciclopenta[a]fenantreno útiles en el tratamiento del dolor y la inflamación
CN116574151B (zh) * 2023-03-13 2026-03-13 奥锐特药业股份有限公司 一种醋酸阿比特龙及其中间体的制备方法
CN116178475B (zh) * 2023-03-13 2025-07-29 奥锐特药业股份有限公司 一种醋酸阿比特龙及其中间体的制备方法
US20250296952A1 (en) * 2022-05-06 2025-09-25 Aurisco Pharmaceutical Co., Ltd. Method for preparing abiraterone acetate and intermediate thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026320A (en) * 1958-11-28 1962-03-20 Syntex Sa Derivatives of cortisone and hydrocortisone
JPS4122178Y1 (de) * 1964-12-16 1966-11-04
US3681410A (en) * 1970-08-07 1972-08-01 Syntex Corp Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof
BE792321A (fr) * 1971-12-08 1973-06-05 Roussel Uclaf Nouveaux 18,19-dinor 13,beta-alcoyl pregna 4,9,11-trienes et procede depreparation
ES427522A1 (es) 1973-06-25 1976-12-16 Scherico Ltd Un procedimiento para la preparacion de un 3-ceto-6-arido-4.6-bis-deshidroesteroide.
CH606090A5 (de) * 1974-07-30 1978-10-13 Ciba Geigy Ag
GB1490852A (en) * 1974-09-12 1977-11-02 Leo Pharm Prod Ltd Fusidic acid derivatives
US5002961A (en) * 1987-10-19 1991-03-26 Merrell Dow Pharmaceuticals Method for reducing injury with imidazol-2-thionecarboxamides
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
DK603988D0 (da) * 1988-10-28 1988-10-28 Klaus Bendtzen Farmaceutisk praeparat
DE4005516A1 (de) * 1989-02-24 1990-08-30 Henkel Corp Verfahren zur umwandlung (alpha)-acetyl-substituierter lactone in (alpha)-alkyliden-substituierte lactone
US5079239A (en) * 1990-02-16 1992-01-07 Harbor Branch Oceanographic Institution, Inc. Sterol disulfates and methods of use
US5219879A (en) * 1990-03-05 1993-06-15 Du Pont Merck Pharmaceutical Company Heterocyclic steroid compounds
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
CA2086221C (en) * 1992-12-23 2003-07-15 Raymond J. Andersen Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent
US5506221A (en) * 1992-12-24 1996-04-09 University Of British Columbia Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agents
US5763435A (en) * 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders

Also Published As

Publication number Publication date
DE69717633T2 (de) 2003-10-02
RU2196143C2 (ru) 2003-01-10
US20040162425A1 (en) 2004-08-19
US6046185A (en) 2000-04-04
US6706701B1 (en) 2004-03-16
JP2001503732A (ja) 2001-03-21
NZ333731A (en) 2000-09-29
EP0917534B1 (de) 2002-12-04
KR20000023661A (ko) 2000-04-25
US7067682B2 (en) 2006-06-27
CA2259981C (en) 2008-06-10
AU722815B2 (en) 2000-08-10
DE69717633D1 (de) 2003-01-16
US6949533B2 (en) 2005-09-27
US20040157814A1 (en) 2004-08-12
US20060211857A1 (en) 2006-09-21
BR9710353A (pt) 2000-01-11
AU3332397A (en) 1998-02-09
CA2259981A1 (en) 1998-01-22
WO1998002450A2 (en) 1998-01-22
ES2187788T3 (es) 2003-06-16
EP0917534A2 (de) 1999-05-26
KR100533436B1 (ko) 2006-01-09

Similar Documents

Publication Publication Date Title
DE69717633D1 (de) 6,7-oxygenierte steroide und deren verwendung
MX9303826A (es) Glicosidos esteroidales como agentes hipocolesterolemicos y agentes antiaterosclerosis.
ES2155874T3 (es) Composiciones cosmeticas que contienen acido betulinico.
BR0014189A (pt) Derivados de ácidos substituìdos úteis como agentes antidiabéticos e antiobesidade e método
TR199701544T1 (xx) Yeni dolastatin t�revleri,bunlar�n haz�rlanmas� ve kullan�lmas�.
ATE206035T1 (de) Haferextrakte enthaltende sonnenschutzmittel
ES2124668B1 (es) "nuevosl-arilpirazoles con propiedades plaguicidas.
ATE241337T1 (de) Hautpflegemittel für gealterte haut
NO950626L (no) Middel for transdermal applikasjon inneholdende 3-ketodesogestrel
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
ES2105551T3 (es) Utilizacion de derivados de la resorcina substituidos en posicion(es) 4,4 y 5 o 4 y 6 en unas composiciones cosmeticas o dermofarmaceuticas con accion despigmentante.
TR200003377T2 (tr) Estrojenler ile bütünleşik 2-fenil-1-[4-(2-aminoetoksi)benzil]-indol
ATE197799T1 (de) Steroid-nitrit und nitrat-ester-verbindungen und ihre verwendung als antiphlogistische medikamente
MX9303594A (es) Oximas piridino, pirrolidino y azepino substituidas utiles como agentes antiateroscleroticos y antihipercolesterolemicos.
DE69523622D1 (de) Diastereomerenreine 3-oxo und 3-thioxo-4-aza-androstanderivate und ihre verwendung als antiandrogene
AU4584901A (en) Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
ATE378073T1 (de) Von cyclodextrinen stabilisierter radiopharmazeutischer reagenzsatz
DE60123242D1 (de) Verwendung von (1-ethoxyethoxy)cyclododecan in einer parfümzusammensetzung als fixiermittel und/oder parfümverstärker
NO842408L (no) Fremgangsmaate ved fremstilling av 1-alkyl-androsta-1,4-dien-3,17-dioner
PT1135403E (pt) 17beta-acil-19alfa-propinil-11beta-arilesteroides e os seus derivados que tem propriedades hormonais agonistas ou antagonistas
DE69939171D1 (de) Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
FI890302L (fi) Parannus androsta-1,4-dieeni-3,17-dionin 6-metyleenijohdannaisten synteesissä
ATE451107T1 (de) 3-o-sulfamatsteroidderivate als hemmer von estronsulfatase
NO20023276D0 (no) Fremgangsmåte til å fremstille betulinsyre
ATE154607T1 (de) Neue steroide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0917534

Country of ref document: EP

REN Ceased due to non-payment of the annual fee